ARTICLE | Clinical News
Botulism antitoxin heptavalent regulatory update
April 1, 2013 7:00 AM UTC
FDA approved a BLA from Cangene for botulism antitoxin heptavalent (BAT) to treat patients showing signs of botulism following documented or suspected exposure to botulinum neurotoxin. The approval tr...